Hormonal therapy

DRUG4 trials

Sponsors

University of Alabama at Birmingham, Vanderbilt-Ingram Cancer Center, Hoffmann-La Roche, University of Colorado, Denver

Conditions

Breast CancerCardiovascularMenopauseMenopause Hot FlashesMenopause Related ConditionsMetastatic Breast Cancer

Phase 2

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

CompletedNCT00240071

University of Alabama at BirminghamMetastatic Breast Cancer

Start: 2005-10-31End: 2011-04-30Updated: 2019-10-30

A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer

CompletedNCT01142778

Hoffmann-La RocheBreast Cancer

Start: 2010-05-19End: 2017-12-13Updated: 2018-03-16

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Not yet recruitingNCT06975111

University of Colorado, DenverCardiovascular, Menopause, Menopause Hot Flashes +1

Start: 2026-03-01End: 2030-10-01Target: 200Updated: 2026-03-09

Unknown Phase

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

CompletedNCT00647218

Vanderbilt-Ingram Cancer CenterBreast Cancer

Start: 2000-02-29End: 2004-11-30Updated: 2017-02-23

Related Papers

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.

2020-11-046 citations

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

2014-10-3094 citations